Table 5 Univariable analysis in the ICU patients after matching
From: Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
ICU | |||
|---|---|---|---|
Case group (n = 9) | Control group (n = 36) | P | |
Age, years, mean ± SD | 54.58 ± 23.02 | 55.13 ± 22.08 | 0.977 |
Sex, n (%) | > 0.999 | ||
Male | 6 | 24 | |
Female | 3 | 12 | |
Allergy history, n (%) | 0 | 0 | – |
Disease history, n (%) | 8 | 26 | 0.544 |
Infection history, n (%) | 1 | 3 | 0.798 |
Surgery history, n (%) | 5 | 11 | 0.311 |
Smoking/drinking/drug use, n (%) | 1 | 4 | > 0.999 |
Combined with other drugs, n (%) | 9 | 0 | 0.001 |